Company Overview and News

254
AVEO / AVEO Pharmaceuticals, Inc. FORM 8-K (Current Report)

18h sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
AVEO

245
AVEO Pharmacueticals: Handicapping TIVO-3

2018-06-20 seekingalpha
AVEO Pharmaceuticals (AVEO) is developing it's lead product tivozinib for use in Renal Cell Carcinoma (RCC).
AVEO

339
My Top Picks With A 1-Year Time Frame

2018-06-14 seekingalpha
I typically have been too early on my calls so far as an investor and contributor on Seeking Alpha.
RSO.PRC ETP.PRC RDS.B BRGYY RDS.A RSO.PRBCL VSTM RSO.PRACL RDSB RDSA ADMS BG BRGXF ETP AVEO XAN RYDBF RYDAF RSO.PRA RSO RSO.PRB

472
Has A New Advaxis Awakened Out Of The Doldrums?

2018-06-08 seekingalpha
Advaxis has reformed its management team, with a new CEO and CFO, and a CMO after a long search.
AZN AMGN ADXS AVEO AZN

352
Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?

2018-06-08 zacks
Investors in AVEO Pharmaceuticals, Inc. (AVEO - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $3.00 Call had some of the highest implied volatility of all equity options today.
BRQS AVEO MU LB

265
Why Is AVEO Pharmaceuticals (AVEO) Down 1.6% Since Its Last Earnings Report?

2018-06-07 zacks
It has been about a month since the last earnings report for AVEO Pharmaceuticals, Inc. (AVEO - Free Report) . Shares have lost about 1.6% in that time frame.
AVEO ENL CRAI ENDP

256
Gemphire Therapeutics started at outperform with $22 stock price target

2018-05-16 marketwatch
Analysts have been eager to weigh in on the Healthcare sector with new ratings on ...[...]
AVEO IMDZ GEMP

255
AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected

2018-05-09 zacks
AVEO Pharmaceuticals, Inc. (AVEO - Free Report) reported first-quarter 2018 loss of 8 cents per share, wider than the Zacks Consensus Estimate of a loss of 7 cents but narrower than the year-ago loss of 12 cents. However, excluding gains related to a change in fair value of warrant liability, the company reported a loss of 6 cents per share.
HTGZ AVEO LGNZZ LGND LGNYZ LGNXZ HTGC MYGN LGNDZ HTGX HTGY

259
AVEO / AVEO Pharmaceuticals, Inc. 8-K (Current Report)

2018-05-08 sec.gov
aveo-8k_20180508.htm UNITED STATES
AVEO

255
AVEO / AVEO Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov
aveo-10q_20180331.htm UNITED STATES
AVEO

260
AVEO / AVEO Pharmaceuticals, Inc. DEFA14A

2018-04-27 sec.gov
aveo-defa14a_20180618.htm UNITED STATES
AVEO

256
AVEO / AVEO Pharmaceuticals, Inc. DEF 14A

2018-04-27 sec.gov
aveo-def14a_20180618.htm UNITED STATES
AVEO

241
AVEO / AVEO Pharmaceuticals, Inc. null

2018-04-26 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;[email protected](O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](")-C;@<2G,PQ,C P'0+(,C.C$?\;)?P "# #6=0?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HV,2 P(&]B:@T\/"]#(#8Y+T9I;'1E
AVEO

241
AVEO / AVEO Pharmaceuticals, Inc. null

2018-04-26 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;[email protected](O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](")[email protected]@<2G7PQ,C P'0+(,C.C$?\;)?P "# #5CP?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HV,2 P(&]B:@T\/"]#(#8Y+T9I;'1E
AVEO

275
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock

2018-04-23 zacks
Investors in AVEO Pharmaceuticals, Inc. (AVEO - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 19th 2018 $1.50 Put had some of the highest implied volatility of all equity options today.
[DXPE] SGC NINE DXPE AVEO ALK

AVEO : AVEO Pharmaceuticals Stock Analysis and Research Report

2017-10-02 - Asif

AVEO Pharmaceuticals is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company proprietary platform has delivered unique insights into cancer and related diseases. The company's strategy is to leverage these biomarker insights and partner resources to advance the development of its clinical pipeline. The company is focused on developing its lead candidate tivozanib in North America as a treatment for renal cell carcinoma, or RCC. In addition, The company has entered into partnerships to fund the further development and commercialization of its clinical stage assets, including AV-380, ficlatuzumab, AV-203, and tivozanib for oncology indications outside of North America. The company is currently seeking a partner to develop the AV-353 platform, a preclinical asset, worldwide for the potential treatment of pulmonary arterial hypertension, or PAH. Going Concern AVEO Pharmaceutic...

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

12h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to AVEO / AVEO Pharmaceuticals, Inc. on message board site Silicon Investor.

AVEO Pharmaceuticals
CUSIP: 053588109